| P50 | author | Alessandro Busca | Q49707069 |
| | Giuseppe Milone | Q50863047 |
| | Marco Picardi | Q57318742 |
| | Livio Pagano | Q88052025 |
| | Simone Cesaro | Q40475424 |
| P2093 | author name string | A Candoni | |
| | A Nosari | |
| | L Melillo | |
| | R Fanin | |
| | M Caira | |
| | M Delia | |
| | R Fanci | |
| | C Cattaneo | |
| | A Bonini | |
| | M Giacchino | |
| | C Caramatti | |
| | R Scime' | |
| | SEIFEM GROUP (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne) | |
| P2860 | cites work | Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 |
| | Rationale for combination antifungal therapy | Q34335236 |
| | Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. | Q34455633 |
| | Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study | Q34543097 |
| | Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | Q34936576 |
| | Toward more effective antifungal therapy: the prospects of combination therapy. | Q35828187 |
| | Decision making in antifungal monotherapy versus combination therapy | Q36484950 |
| | Combination antifungal therapy: what can and should we expect? | Q36847555 |
| | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients | Q36895540 |
| | Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogr | Q37036246 |
| | Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria | Q37164085 |
| | Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis | Q37204192 |
| | Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). | Q37293269 |
| | In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. | Q39651019 |
| | A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis | Q41644134 |
| | Combination echinocandin-polyene treatment of murine mucormycosis | Q41904884 |
| | Combination antifungal therapy for cryptococcal meningitis | Q41924502 |
| | Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis | Q42201210 |
| | Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. | Q42286250 |
| | Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? | Q42954068 |
| | Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. | Q42958723 |
| | Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin | Q44304226 |
| | A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients | Q44355090 |
| | Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients | Q44355277 |
| | Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus | Q44418762 |
| | Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin | Q44469440 |
| | Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies | Q44519647 |
| | Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality--SEIFEM-C Report | Q44664129 |
| | Combination antifungal therapy for invasive aspergillosis | Q45096994 |
| | Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. | Q45938423 |
| | Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). | Q45945768 |
| | European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update | Q46050924 |
| | Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis | Q46265389 |
| | Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis | Q46448567 |
| | Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). | Q46946844 |
| P433 | issue | 6 | |
| P304 | page(s) | 342-350 | |
| P577 | publication date | 2013-12-23 | |
| P1433 | published in | Mycoses | Q1956531 |
| P1476 | title | Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study | |
| P478 | volume | 57 | |